Some Current Ideas on the Pathogenesis and the Role of Neuroprotection in Glaucomatous Optic Neuropathy

European Journal of Ophthalmology

Volumn 13, Issue 3_suppl, 2003, Pages 19-26

  Osborne, N N ^a   Chidlow, G ^a   Wood, J ^a   Casson, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Ganglion cell death; Glaucoma; Neuroprotection; Optic neuropathy

Indexed keywords

NEUROPROTECTIVE AGENT;

ANIMAL; APOPTOSIS; CELL PROTECTION; DRUG EFFECT; GLAUCOMA; HUMAN; OPTIC DISK; OPTIC NERVE DISEASE; PATHOLOGY; RETINA GANGLION CELL; REVIEW;

ANIMALS; APOPTOSIS; CYTOPROTECTION; GLAUCOMA; HUMANS; NEUROPROTECTIVE AGENTS; OPTIC DISK; OPTIC NERVE DISEASES; RETINAL GANGLION CELLS;

MLCS; MLOWN;

EID: 0038644595     PISSN: 11206721     EISSN: 17246016     Source Type: Journal    
DOI: 10.1177/112067210301303S04     Document Type: Article

References (77)

1. World Health Organization Blindness and visual disability: major causes world wide. Geneva 1997; WHO.
2. Tielsch J.M.. The epidemiology and control of open angle glaucoma: a population-based perspective. Annu Rev Public Health 1996; 17: 121–36.
3. Sommer A. Tielsch J.M. Katz J. et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991; 109: 1090–5.
4. Gupta N. Weinreb R.N.. New definitions of glaucoma. Curr Opin Ophthalmol 1997; 8: 38–41.
5. Tielsch J.M. Katz J. Singh K. Quigley H.A. Gottsch J.D. Javitt J. Sommer A.. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol 1991; 134: 1102–10.
6. Van Buskirk E.M. Cioffi G.A.. Glaucomatous optic neuropathy. Am J Ophthalmol 1992; 113: 447–52.
7. Flammer J. Orgul S.. Optic nerve blood-flow abnormalities in glaucoma. Prog Retin Eye Res 1998; 1: 267–89.
8. Hayreh S.S.. The role of age and cardiovascular disease in glaucomatous optic neuropathy. Surv Ophthalmol 1999; 43(Suppl): S27–42.
9. Osborne N.N. Chidlow G. Nash M.S. Wood J.P.. The potential of neuroprotection in glaucoma treatment. Curr Opin Ophthalmol 1999; 10: 82–92.
10. Osborne N.N. Ugarte M. Chao M. et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol 1999; 43: 1s102–28.
11. Osborne N.N. Wood J.P. Chidlow G. Bae J.H. Melena J. Nash M.S.. Ganglion cell death in glaucoma: what do we really know? Br J Ophthalmol 1999; 83: 980–6.
12. Osborne N. Melena J. Chidlow G. Wood J.. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. BJ Ophthalmol 2001; 85: 1252–9.
13. Weinreb R.N. Levin L.A.. Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol 1999; 117: 1540–4.
14. Graefe Av. Uber die Iridectomie bei Glaukom und uber den glaucomatosen Prozess. Graefes Arch Clin Exp Ophthalmol 1857; 3: 456–555.
15. Quigley H.A. Enger C. Katz J. Sommer A. Scott R. Gilbert D.. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol 1994; 112: 644–9.
16. Chauhan B.C. Drance S.M.. The relationship between intraocular pressure and visual field progression in glaucoma. Graefes Arch Clin Exp Ophthalmol 1992; 230: 521–6.
17. Roth S.M. Spaeth G.L. Starita R.J. Birbillis E.M. Steinmann W.C.. The effects of postoperative corticosteroids on trabeculectomy and the clinical course of glaucoma: five-year follow-up study. Ophthalmic Surg 1991; 22: 724–9.
18. Leske M.C. Heijl A. Hussein M. Bengtsson B. Hyman L. Komaroff E.. Factors for glaucoma progression and the effect of treatment: early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48–56.
19. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487–97.
20. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429–40.
21. Fechtner R.D. Weinreb R.N.. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol 1994; 39: 23–42.
22. Levy N.S. Crapps E.E.. Displacement of optic nerve head in response to short-term intraocular pressure elevation in human eyes. Arch Ophthalmol 1984; 102: 782–6.
23. Yan D.B. Coloma F.M. Metheetrairut A. Trope G.E. Heathcote J.G. Ethier C.R.. Deformation of the lamina cribrosa by elevated intraocular pressure. Br J Ophthalmol 1994; 78: 643–8.
24. Jafari S.S. Nielson M. Graham D.I. Maxwell W.L.. Axonal cytoskeletal changes after nondisruptive axonal injury. II. Intermediate sized axons. J Neurotrauma 1998; 15: 955–66.
25. Jafari S.S. Maxwell W.L. Neilson M. Graham D.I.. Axonal cytoskeletal changes after non-disruptive axonal injury. J Neurocytol 1997; 26: 207–21.
26. Quigley H.A. McKinnon S.J. Zack D.J. et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 2000; 41: 3460–6.
27. Pease M.E. McKinnon S.J. Quigley H.A. Kerrigan Baumrind L.A. Zack D.J.. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 764–74.
28. Hernandez M.R. Pena J.D. Selvidge J.A. Salvador Silva M. Yang P.. Hydrostatic pressure stimulates synthesis of elastin in cultured optic nerve head astrocytes. Glia 2000; 32: 122–36.
29. Hernandez M.R.. The optic nerve head in glaucoma: role of astrocytes in tissue remodeling. Prog Retin Eye Res 2000; 19: 297–321.
30. Zhao D.Y. Cioffi G.A.. Anterior optic nerve microvascular changes in human glaucomatous optic neuropathy. Eye 2000; 14(Pt 3B): 445–9.
31. Quigley H.A. Green W.R.. The histology of human glaucoma cupping and optic nerve damage: clinicopathologic correlation in 21 eyes. Ophthalmology 1979; 86: 1803–30.
32. Quigley H.A. Addicks E.M. Green W.R. Maumenee A.E.. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol 1981; 99: 635–49.
33. Quigley H.A. Hohman R.M. Addicks E.M. Green W.R.. Blood vessels of the glaucomatous optic disc in experimental primate and human eyes. Invest Ophthalmol Vis Sci 1984; 25: 918–31.
34. Guyton A.. Textbook of Medical Physiology. 7th ed Philadelphia: W. B. Saunders, 1986; 230–5.
35. Quigley H.A. Hohman R.M. Sanchez R. Addicks E.M.. Optic nerve head blood flow in chronic experimental glaucoma. Arch Ophthalmol 1985; 103: 956–62.
36. Grunwald J.E. Sinclair S.H. Riva C.E.. Autoregulation of the retinal circulation in response to decrease of intraocular pressure below normal. Invest Ophthalmol Vis Sci 1982; 23: 124–7.
37. Evans D.W. Harris A. Garrett M. Chung H.S. Kagemann L.. Glaucoma patients demonstrate faulty autoregulation of ocular blood flow during posture change. Br J Ophthalmol 1999; 83: 809–13.
38. Tielsch J.M. Katz J. Sommer A. Quigley H.A. Javitt J.C.. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol 1995; 113: 216–21.
39. Grunwald J.E. Riva C.E. Stone R.A. Keates E.U. Petrig B.L.. Retinal autoregulation in open-angle glaucoma. Ophthalmology 1984; 91: 1690–4.
40. Harris A. Harris M. Biller J. Garzozi H. Zarfty D. Ciulla T.A. Martin B.. Aging affects the retrobulbar circulation differently in women and men. Arch Ophthalmol 2000; 118: 1076–80.
41. Hayreh S.S. Bill A. Sperber G.O.. Effects of high intraocular pressure on the glucose metabolism in the retina and optic nerve in old atherosclerotic monkeys. Graefes Arch Clin Exp Ophthalmol 1994; 232: 745–52.
42. Graham S.L. Drance S.M.. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol 1999; 43(Suppl 1): S10–6.
43. Hayreh S.S. Podhajsky P. Zimmerman M.B.. Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica 1999; 213: 76–96.
44. Mitchell P. Smith W. Chey T. Healey P.R.. Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology 1997; 104: 712–8.
45. Sommer A.. Glaucoma risk factors observed in the Baltimore Eye Survey. Curr Opin Ophthalmol 1996; 7: 93–8.
46. Tielsch J.M. Katz J. Quigley H.A. Javitt J.C. Sommer A.. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology 1995; 102: 48–53.
47. Gasser P. Flammer J.. Blood-cell velocity in the nailfold capillaries of patients with normal-tension and high-tension glaucoma. Am J Ophthalmol 1991; 111: 585–8.
48. Drance S.M. Douglas G.R. Wijsman K. Schulzer M. Britton R.J.. Response of blood flow to warm and cold in normal and low-tension glaucoma patients. Am J Ophthalmol 1988; 105: 35–9.
49. Flammer J. Eppler E. Niesel P.. Die quantitative Perimetrie beim Glaukompatienten ohne lokale Gesichtsfelddefekte. [Quantitative perimetry in the glaucoma patient without local visual field defects]. Graefes Arch Clin Exp Ophthalmol 1982; 219: 92–4.
50. Nicolela M.T. Drance S.M.. Various glaucomatous optic nerve appearances: clinical correlations. Ophthalmology 1996; 103: 640–9.
51. Schulzer M. Drance S.M. Carter C.J. Brooks D.E. Douglas G.R. Lau W.. Biostatistical evidence for two distinct chronic open angle glaucoma populations. Br J Ophthalmol 1990; 74: 196–200.
52. Niesel P. Flammer J.. Correlations between intraocular pressure, visual field and visual acuity, based on 11 years of observations of treated chronic glaucomas. Int Ophthalmol 1980; 3: 31–5.
53. Osborne N.N. Melena J. Chidlow G. Wood J.P.. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol 2001; 85: 1252–9.
54. Vorwerk C.K. Naskar R. Schuettauf F. et al. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Invest Ophthalmol Vis Sci 2000; 41: 3615–21.
55. Dreyer E.B. Zurakowski D. Schumer R.A. Podos S.M. Lipton S.A.. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996; 114: 299–305.
56. Drago F. Valzelli S. Emmi I. Marino A. Scalia C.C. Marino V.. Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp Eye Res 2001; 72: 479–86.
57. Marcheselli V. Decoster M. Campbell Z. Barreiro S. Bazan N.. Neuroprotection by unoprostone, but not by latanaoprost, against glutamate-stimulated calcium influx and cell death in retinal ganglion cells. Invest Ophthalmol Vis Sci 2001; 42: S750.
58. Yoles E. Wheeler L.A. Schwartz M.. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999; 40: 65–73.
59. Ahmed F.A. Hegazy K. Chaudhary P. Sharma S.C.. Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res 2001; 913: 133–9.
60. Lafuente M.P. Villegas Perez M.P. Sobrado Calvo P. Garcia Aviles A. Miralles de Imperial J. Vidal Sanz M.. Neuroprotective effects of alpha(2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci 2001; 42: 2074–84.
61. Wheeler L.A. Gil D.W. WoldeMussie E.. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol 2001; 45(Suppl): S290–4.
62. Gross R.L. Hensley S.H. Wu S.M.. Retinal ganglion cell dysfunction induced by hypoxia and glutamate: potential neuroprotective effects of β-blockers. Surv Ophthalmol 1999; 43 S162–70.
63. Osborne N.N. De Santis L.M. Bae J.H. et al. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp Eye Res 1999; 69: 331–42.
64. Hicks D. Heidinger V. Mohand Said S. Sahel J. Dreyfus H.. Growth factors and gangliosides as neuroprotective agents in excitotoxicity and ischemia. Gen Pharmacol 1998; 30: 265–73.
65. Chao H.M. Osborne N.N.. Topically applied clonidine protects the rat retina from ischaemia/reperfusion by stimulating alpha(2)-adrenoceptors and not by an action on imidazoline receptors. Brain Res 2001; 904: 126–36.
66. Melena J. Wood J.P.M. Osborne N.N.. Betaxolol, a b1-adrenoceptor antagonist, has an affinity for L-type Ca2+ channels. Eur J Pharmacol 1999; 378 317–22.
67. Chidlow G. Melena J. Osborne N.N.. Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br J Pharmacol 2000; 130: 759–66.
68. Osborne N.N. Chidlow G. Wood J.P. Schmidt K.G. Casson R. Melena J.. Expectations in the treatment of retinal diseases: neuroprotection. Curr Eye Res 2001; 22: 321–32.
69. Melena J. Stanton D. Osborne N.N.. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch Clin Exp Ophthalmol 2001; 239: 522–30.
70. Hirooka K. Kelly M.E. Baldridge W.H. Barnes S.. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp Eye Res 2000; 70: 611–21.
71. Messmer C. Flammer J. Stumpfig D.. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol 1991; 112: 678–81.
72. Vainio Jylha E. Vuori M.L.. The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study. Graefes Arch Clin Exp Ophthalmol 1999; 237: 100–4.
73. Evans D.W. Harris A. Cantor L.B.. Primary open-angle glaucoma patients characterized by ocular vasospasm demonstrate a different ocular vascular response to timolol versus betaxolol. J Ocul Pharmacol Ther 1999; 15: 479–87.
74. Drance S.M.. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J Glaucoma 1998; 7: 247–52.
75. Collignon Brach J.. Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv Ophthalmol 1994; 38(Suppl): S149–55.
76. Kaiser H.J. Flammer J. Stumpfig D. Hendrickson P.. Longterm visual field follow-up of glaucoma patients treated with β-blockers. Surv Ophthalmol 1994; 38(Suppl): S156–9; Discussion S60.
77. Collignon Brach J.. Long-term effect of ophthalmic beta-adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma. Curr Eye Res 1992; 11: 1–3.